ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,681 to 2,700 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Folic Acid 4 mg vs Placebo: Stillbirth15 of 1,364

26 of 1,374

-0.8 points

-1.8 to 0.1

2,738NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Eplerenone: Double-blind Phase vs Placebo: Double-blind Phase: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date249 of 1,364

356 of 1,373

-7.7 points

-10.8 to -4.6

2,737NCT00232180

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

Abiraterone vs Enzalutamide: deaths from any cause1,007 of 1,316

1,036 of 1,415

3.3 points

0.0 to 6.5

2,731NCT05968599

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Home Monitoring Guided OAC vs Physician-Directed OAC: Rates of All-cause Mortality147 of 1,357

140 of 1,361

0.5 points

-1.8 to 2.9

2,718NCT00559988

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

Home Monitoring Guided OAC vs Physician-Directed OAC: Rate of Major Bleeding Events46 of 1,357

34 of 1,361

0.9 points

-0.4 to 2.2

2,718NCT00559988

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

Home Monitoring Guided OAC vs Physician-Directed OAC: serious adverse events372 of 1,357

374 of 1,361

-0.1 points

-3.4 to 3.3

2,718NCT00559988

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

Associated With Rotigotine vs Not Associated With Rotigotine: serious adverse events261 of 1,390

269 of 1,328

-1.5 points

-4.5 to 1.5

2,718NCT00599339

Transdermal Rotigotine User Surveillance Study

Single MDA vs Repeated MDA: deaths from any cause5 of 1,265

15 of 1,447

-0.6 points

-1.3 to 0.0

2,712NCT02509481

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

Single MDA vs Repeated MDA: serious adverse events10 of 1,265

19 of 1,447

-0.5 points

-1.3 to 0.3

2,712NCT02509481

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

Arm I:Sentinel Node Resection+Conventional Axillary Dissection vs Arm II: Sentinel Node Resection Followed by Node Examination: Morbidity - Number of Participants With Residual Arm Numbness408 of 1,336

103 of 1,371

23.0 points

20.2 to 25.9

2,707NCT00003830

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalizations, Emergency Department (ED) Visits, Observation Stays, and Deaths883 of 1,358

864 of 1,349

1.0 points

-2.6 to 4.6

2,707NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With COPD Exacerbation689 of 1,358

706 of 1,349

-1.6 points

-5.4 to 2.2

2,707NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Observation Stays295 of 1,358

269 of 1,349

1.8 points

-1.3 to 4.8

2,707NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Emergency Department Visits702 of 1,358

694 of 1,349

0.2 points

-3.5 to 4.0

2,707NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalizations502 of 1,358

499 of 1,349

-0.0 points

-3.7 to 3.6

2,707NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays411 of 1,358

398 of 1,349

0.8 points

-2.7 to 4.2

2,707NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Deaths Among Participants117 of 1,358

117 of 1,349

-0.1 points

-2.2 to 2.1

2,707NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: deaths from any cause117 of 1,358

117 of 1,349

-0.1 points

-2.2 to 2.1

2,707NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: serious adverse events502 of 1,358

499 of 1,349

-0.0 points

-3.7 to 3.6

2,707NCT02478359

Walk On! Physical Activity Coaching

Navigator Arm vs Non-Intervention Arm: Number of Participants Who do Not Receive Diagnostic Audiological Testing (Aim 1)378 of 1,601

336 of 1,098

-7.0 points

-10.4 to -3.6

2,699NCT03875339

Communities Helping the Hearing of Infants by Reaching Parents

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=135"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=135

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01355159-8454f45d",
        "title": "Folic Acid 4 mg vs Placebo: Stillbirth",
        "summary": "15 of 1364 against 26 of 1374; risk difference -0.8 points, 95% interval -1.8 to 0.1; NCT01355159, High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention",
        "record": "/library/comparisons/NCT01355159-8454f45d",
        "nct_id": "NCT01355159",
        "kind": "outcome",
        "participants": 2738,
        "risk_difference": {
          "value": -0.007925785535308004,
          "lower": -0.01760378463848837,
          "upper": 0.0013307635112100417
        },
        "group_1": "15 of 1,364",
        "group_2": "26 of 1,374",
        "difference": "-0.8 points",
        "interval": "-1.8 to 0.1",
        "trial_title": "High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention"
      },
      {
        "id": "NCT00232180-9e4d5c6a",
        "title": "Eplerenone: Double-blind Phase vs Placebo: Double-blind Phase: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date",
        "summary": "249 of 1364 against 356 of 1373; risk difference -7.7 points, 95% interval -10.8 to -4.6; NCT00232180, A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines",
        "record": "/library/comparisons/NCT00232180-9e4d5c6a",
        "nct_id": "NCT00232180",
        "kind": "outcome",
        "participants": 2737,
        "risk_difference": {
          "value": -0.07673491487484863,
          "lower": -0.1075893893470811,
          "upper": -0.0457049385479094
        },
        "group_1": "249 of 1,364",
        "group_2": "356 of 1,373",
        "difference": "-7.7 points",
        "interval": "-10.8 to -4.6",
        "trial_title": "A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=136",
  "request_id": "A53hJPnMLgnbdcsa"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?